RLAY Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -784.14% compared to Relay Therapeutics, Inc.'s net margin of 34.4%. Relay Therapeutics, Inc.'s return on equity of -41.4% beat Eli Lilly & Co.'s return on equity of 104.39%.

Relay Therapeutics, Inc. has a consensus price target of $15.64, signalling upside risk potential of 54.05%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 21%. Given that Relay Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Relay Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Relay Therapeutics, Inc. has a beta of 1.551, which suggesting that the stock is 55.115% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Relay Therapeutics, Inc. quarterly revenues are $7M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Relay Therapeutics, Inc.'s net income of -$54.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 113.41x versus 14.03x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -784.14% compared to Relay Therapeutics, Inc.'s net margin of --. Relay Therapeutics, Inc.'s return on equity of -41.4% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Relay Therapeutics, Inc. has a consensus price target of $15.64, signalling upside risk potential of 54.05%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $129.35 which suggests that it could grow by 27.83%. Given that Relay Therapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Revolution Medicines, Inc..

Relay Therapeutics, Inc. has a beta of 1.551, which suggesting that the stock is 55.115% more volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.875%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are $7M, which are larger than Revolution Medicines, Inc. quarterly revenues of --. Relay Therapeutics, Inc.'s net income of -$54.9M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 113.41x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spyre Therapeutics, Inc. has a net margin of -784.14% compared to Relay Therapeutics, Inc.'s net margin of --. Relay Therapeutics, Inc.'s return on equity of -41.4% beat Spyre Therapeutics, Inc.'s return on equity of -25.86%.

Relay Therapeutics, Inc. has a consensus price target of $15.64, signalling upside risk potential of 54.05%. On the other hand Spyre Therapeutics, Inc. has an analysts' consensus of $58.57 which suggests that it could grow by 42.86%. Given that Relay Therapeutics, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Spyre Therapeutics, Inc..

Relay Therapeutics, Inc. has a beta of 1.551, which suggesting that the stock is 55.115% more volatile than S&P 500. In comparison Spyre Therapeutics, Inc. has a beta of 3.086, suggesting its more volatile than the S&P 500 by 208.563%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Spyre Therapeutics, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are $7M, which are larger than Spyre Therapeutics, Inc. quarterly revenues of --. Relay Therapeutics, Inc.'s net income of -$54.9M is lower than Spyre Therapeutics, Inc.'s net income of -$51.8M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Spyre Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 113.41x versus 701.12x for Spyre Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tyra Biosciences, Inc. has a net margin of -784.14% compared to Relay Therapeutics, Inc.'s net margin of --. Relay Therapeutics, Inc.'s return on equity of -41.4% beat Tyra Biosciences, Inc.'s return on equity of -39.76%.

Relay Therapeutics, Inc. has a consensus price target of $15.64, signalling upside risk potential of 54.05%. On the other hand Tyra Biosciences, Inc. has an analysts' consensus of $49.51 which suggests that it could grow by 40.38%. Given that Relay Therapeutics, Inc. has higher upside potential than Tyra Biosciences, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Tyra Biosciences, Inc..

Relay Therapeutics, Inc. has a beta of 1.551, which suggesting that the stock is 55.115% more volatile than S&P 500. In comparison Tyra Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tyra Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Tyra Biosciences, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are $7M, which are larger than Tyra Biosciences, Inc. quarterly revenues of --. Relay Therapeutics, Inc.'s net income of -$54.9M is lower than Tyra Biosciences, Inc.'s net income of -$33.8M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Tyra Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 113.41x versus -- for Tyra Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.